These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 27537734)

  • 21. Effect of Bosentan on systemic sclerosis-associated interstitial lung disease ineligible for cyclophosphamide therapy: a prospective open-label study.
    Furuya Y; Kuwana M
    J Rheumatol; 2011 Oct; 38(10):2186-92. PubMed ID: 21885489
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis.
    Seibold JR; Denton CP; Furst DE; Guillevin L; Rubin LJ; Wells A; Matucci Cerinic M; Riemekasten G; Emery P; Chadha-Boreham H; Charef P; Roux S; Black CM
    Arthritis Rheum; 2010 Jul; 62(7):2101-8. PubMed ID: 20506355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Digital ulcers in systemic sclerosis: use of endotheline antagonists].
    Mota J; Castellano A; Santiago F; Carvalho P; Madeira AS; Pereira De Moura JM; Nascimento Costa JM
    Acta Med Port; 2011; 24(5):837-42. PubMed ID: 22525638
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bosentan improves exercise capacity in adolescents and adults after Fontan operation: the TEMPO (Treatment With Endothelin Receptor Antagonist in Fontan Patients, a Randomized, Placebo-Controlled, Double-Blind Study Measuring Peak Oxygen Consumption) study.
    Hebert A; Mikkelsen UR; Thilen U; Idorn L; Jensen AS; Nagy E; Hanseus K; Sørensen KE; Søndergaard L
    Circulation; 2014 Dec; 130(23):2021-30. PubMed ID: 25446057
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liver impairment after concomitant administration of bosentan and clarithromycin in systemic sclerosis.
    Caramaschi P; Mahamid H; Bambara LM; Biasi D
    Joint Bone Spine; 2010 Jan; 77(1):81-2. PubMed ID: 20022782
    [No Abstract]   [Full Text] [Related]  

  • 26. Bosentan as a rescue therapy in scleroderma refractory digital ulcers.
    Chamaillard M; Heliot-Hosten I; Constans J; Taïeb A
    Arch Dermatol; 2007 Jan; 143(1):125-6. PubMed ID: 17224564
    [No Abstract]   [Full Text] [Related]  

  • 27. Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients.
    García de la Peña-Lefebvre P; Rodríguez Rubio S; Valero Expósito M; Carmona L; Gámir Gámir ML; Beltrán Gutiérrez J; Díaz-Miguel C; Orte Martínez J; Zea Mendoza AC
    Rheumatology (Oxford); 2008 Apr; 47(4):464-6. PubMed ID: 18263597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-world effectiveness and safety of bosentan in Japanese patients with systemic sclerosis: A single-center retrospective study.
    Ishikawa M; Endo Y; Yamazaki S; Sekiguchi A; Uchiyama A; Motegi SI
    J Dermatol; 2023 Jun; 50(6):828-832. PubMed ID: 36651000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bosentan for digital ulcers in patients with systemic sclerosis.
    Nagai Y; Hasegawa M; Hattori T; Okada E; Tago O; Ishikawa O
    J Dermatol; 2012 Jan; 39(1):48-51. PubMed ID: 21955007
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting the endothelin axis in scleroderma renal crisis: rationale and feasibility.
    Penn H; Quillinan N; Khan K; Chakravarty K; Ong VH; Burns A; Denton CP
    QJM; 2013 Sep; 106(9):839-48. PubMed ID: 23696678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of digital ulcers in systemic sclerosis: Case series study of thirteen patients and discussion on outcome.
    Abuowda Y; Almeida RS; Oliveira AA; Pego P; Santos C; Matos-Costa J
    Rev Assoc Med Bras (1992); 2017 May; 63(5):422-426. PubMed ID: 28724039
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resolution of severe digital ulceration during a course of Bosentan therapy.
    Snyder MJ; Jacobs MR; Grau RG; Wilkes DS; Knox KS
    Ann Intern Med; 2005 May; 142(9):802-3. PubMed ID: 15867420
    [No Abstract]   [Full Text] [Related]  

  • 33. Bosentan for digital ulcers in patients with systemic sclerosis: a prospective 3-year followup study.
    Tsifetaki N; Botzoris V; Alamanos Y; Argyriou E; Zioga A; Drosos AA
    J Rheumatol; 2009 Jul; 36(7):1550-2. PubMed ID: 19567637
    [No Abstract]   [Full Text] [Related]  

  • 34. Capillary Desertification and Refractory Digital Ulcers in Systemic Sclerosis.
    Zanatta E; Schiavon F; Cozzi F
    J Clin Rheumatol; 2019 Sep; 25(6):e86. PubMed ID: 29561473
    [No Abstract]   [Full Text] [Related]  

  • 35. Potential benefit of bosentan therapy in borderline or less severe pulmonary hypertension secondary to idiopathic pulmonary fibrosis-an interim analysis of results from a prospective, single-center, randomized, parallel-group study.
    Tanaka Y; Hino M; Gemma A
    BMC Pulm Med; 2017 Dec; 17(1):200. PubMed ID: 29237441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful treatment of systemic-sclerosis-related digital ulcers with a selective endothelin type A receptor antagonist (sitaxentan).
    Gholam P; Sehr T; Enk A; Hartmann M
    Dermatology; 2009; 219(2):171-3. PubMed ID: 19590168
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Controlling the digital ulcerative disease in systemic sclerosis is associated with improved hand function.
    Mouthon L; Carpentier PH; Lok C; Clerson P; Gressin V; Hachulla E; Bérezné A; Diot E; Van Kien AK; Jego P; Agard C; Duval-Modeste AB; Sparsa A; Puzenat E; Richard MA;
    Semin Arthritis Rheum; 2017 Jun; 46(6):759-766. PubMed ID: 28214014
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bosentan ameliorated exercise-induced pulmonary arterial hypertension complicated with systemic sclerosis.
    Yagi S; Akaike M; Iwase T; Kusunose K; Niki T; Yamaguchi K; Koshiba K; Yoshida S; Sumitomo-Ueda Y; Aihara K; Hirata Y; Dagvasumberel M; Taketani Y; Tomita N; Yamada H; Soeki T; Wakatsuki T; Matsumoto T; Sata M
    Intern Med; 2010; 49(21):2309-12. PubMed ID: 21048365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of a sequential therapy of bosentan and iloprost versus a monotherapy with bosentan in the treatment of scleroderma related digital ulcers.
    Hafner F; Thomas G; Froehlich H; Steidl K; Brodmann M
    Int Angiol; 2011 Oct; 30(5):493-5. PubMed ID: 21804491
    [No Abstract]   [Full Text] [Related]  

  • 40. A higher degree of criticism about the effectiveness of bosentan for digital ulcers in scleroderma patients, as for interstitial disease, is also necessary: comment on the article by Seibold et al.
    Bredemeier M
    Arthritis Rheum; 2010 Oct; 62(10):3128-9; author reply 3129-30. PubMed ID: 20597113
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.